(Q51521654)

English

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.

scientific article published on 12 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Anthony Harrison

1

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Iain Gardner

2

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Tanya Hay

3

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Maurice Dickins

4

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Kevin Beaumont

5

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Alex Phipps

6

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Lynn Purkins

7

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Gill Allan

8

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Rachelle Christian

9

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Jonathan Duckworth

10

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Ian Gurrell

11

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Sarah Kempshall

12

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Mark Savage

13

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Mark Seymour

14

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Marie Simpson

15

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Louise Taylor

16

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Paul Turnpenny

17

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

language of work or name

0 references

publication date

12 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

42

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

1

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

57-74

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Prediction of human pharmacokinetics--evaluation of methods for prediction of volume of distribution

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Prediction of human pharmacokinetics - renal metabolic and excretion clearance

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Membrane transporters in drug development

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Maraviroc: in vitro assessment of drug-drug interaction potential

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

The Simcyp population-based ADME simulator

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Population-based mechanistic prediction of oral drug absorption

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Innovative early development regulatory approaches: expIND, expCTA, microdosing

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Mechanistic approaches to volume of distribution predictions: understanding the processes.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine.

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: impact of small structural modifications on P-gp recognition and CNS penetration

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.622418

21 January 2018

Identifiers

10.3109/00498254.2011.622418

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/21992032

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51521654&oldid=2143365186"